New Delhi: Noting that the world is witnessing a fourth surge in Covid cases, the government on Friday cautioned people against lowering the guard, particularly during year-end festivities, even as it underlined that infection due to Omicron does not necessarily lead to severe symptomatic disease.
Addressing a joint press conference, ICMR Director-General Dr Balram Bhargava said Delta continues to be the predominant strain in India, including in the recently identified clusters.
"Therefore, we need to continue with the same strategy of following Covid-appropriate behaviour and ramping up vaccination," he said.
Asserting the Omicron variant of Coronavirus does not necessarily lead to severe symptomatic clinical disease, Bhargava said in India, about a third of all the detected cases were mildly symptomatic, and the rest were asymptomatic.
"I want to emphasize that the treatment for Omicron-infected symptomatic individuals remains the same. It does not change from that for Delta, Alpha or the Beta variant," the ICMR DG said.
At the press conference, Union Health Secretary Rajesh Bhushan had a word of caution. "The world is witnessing the fourth surge of COVID-19 cases and the overall positivity is 6.1 per cent. Therefore, we have to be on guard and we can't afford to slacken," he said.
Explaining the Covid trend, including that of all its variants in different continents, Bhushan said that while Europe, North America and Africa were seeing an increase in infection week-on-week since November 26, Asia is
still witnessing a decline in cases. In India, the number of daily cases has been below 10,000 for the last four weeks. "While these numbers are low, we must be vigilant and keep up the guard," the Union health secretary said.
The ministry data updated at 8 am showed that India recorded 6,650 new Coronavirus infections, taking its tally of cases to 3,47,72,626, while the count of active cases has declined to 77,516.
The death toll due to the disease has climbed to 4,79,133, with 374 daily fatalities being recorded, it showed.
He said India has seen two surges in cases — one in September 2020 and another one in May this year. Even as the country's overall cases and deaths are on the decline currently, Kerala, Maharashtra, Tamil Nadu, West Bengal, Karnataka and Mizoram are still reporting a very high number of infections, Bhushan said.
The very high case positivity in Kerala (6.1 per cent) and Mizoram (8.2 per cent) is a cause of concern, he observed.
In 20 districts, including nine in Kerala and eight in Mizoram, the weekly case positivity rate is between five and 10 per cent, and in two districts it is over 10 per cent.
"So, these 22 districts are a cause of concern for us. We are constantly in consultation with the states while central teams are visiting there to give technical support," Bhushan said.
Of the 358 cases of the Omicron variant of Coronavirus reported in India so far, 183 were analysed and it was found that 87 of them were fully vaccinated with three having received booster doses and 70 per cent were asymptomatic, the government said.
Two were partially vaccinated, seven people were unvaccinated while 16 were ineligible to receive vaccine doses in the country's national vaccination programme. The vaccination status of 73 is still unknown, Bhushan said.
He said, 121 cases had foreign travel history, while in 44 cases the infected had come in contact with foreign travellers and information about 18 people were still not available.
About the country's Covid preparedness, the health secretary said 18,10,083 isolation beds, 4,94,314 oxygen-supported beds, 1,39,300 ICU beds, 24,057 paediatric ICU beds, 64,796 paediatric non-ICU beds have been readied.
Also, 50 per cent of the amount under the Emergency Covid Response package (ECRP-II) have been released to states and Union Territories. Using the fund they are reading additional 96,913 oxygen-supported beds, 20,475 ICU beds and 9,574 paediatric non-ICU beds, he said.
On medical oxygen supply, Bhushan said, "Based on global and South Africa's experience, Omicron patients so far did not have additional requirement of oxygen. But we need to be proactive."
During the first wave of Covid infections in the country, the highest requirement of oxygen in a day was 1,000 MT which shot up to 10,000 MT during the second wave.
"There was a ten-fold increase in demand for medical oxygen. We were able to address that because of the collective efforts of Central and state governments and managed to supply 10,000 MT of medical oxygen. Today, we have created a capacity of 18,800 MT of medical oxygen daily," Bhushan said.
Quoting WHO's December 17 guidance, he said that Omicron has a significant growth advantage over Delta, spreading fast through communities, with a doubling time of between 1.5 and three days. Higher risk of transmission compared to Delta has been confirmed by household and contact studies in the United Kingdom, he said.
About vaccination coverage, the health secretary said 89 per cent of India's adult population have received at least one dose of COVID-19 vaccine while 61 per cent have been fully vaccinated.
The cumulative COVID-19 vaccine doses administered in the country crossed the 140-crore landmark milestone on Friday. More than 59 lakh (59,53,621) vaccine doses have been administered till 7 pm on Friday.
In 19 states and Union Territories, first dose coverage was over 90 per cent while in Odisha, Maharashtra, Tamil Nadu, Bihar, Puducherry, Uttar Pradesh, Meghalaya, Jharkhand, Manipur, Punjab and Nagaland the coverage of first and second shots of vaccine was below the national average, he said, adding that it was a cause of concern.
Meanwhile, the Centre on Friday also said Remdesivir drug should only be used in patients with moderate to severe' COVID-19 and those with no renal or hepatic dysfunction within 10 days of the onset of any symptom.
It also warned against use of the drug in patients who are not on oxygen support or in home settings.
According to the clinical guidance issued by the Union health ministry for management of the infection in adult patients, Remdesivir has been asked to be used in patients with moderate to severe COVID-19 and those with no renal or hepatic dysfunction within 10 days of onset of any symptom .
The Tocilizumab drug may be considered for use in the presence of severe disease (preferably within 24 to 48 hours of onset of severe disease/ICU admission), according to the guidelines.
Tocilizumab can be used in case of significantly raised inflammatory markers (CRP &/or IL-6), condition not improving despite use of steroids and no active bacterial/fungal/tubercular infection.
The ministry also said that those above 60 years of age, with cardiovascular disease, hypertension, diabetes and other immunocompromised states are at high risk for severe disease and mortality.
According to the guidelines, Coronavirus patients have been classified into those affected by mild, moderate and severe disease.
For mild disease, home isolation and care is recommended, while admission in a ward is recommended for those battling moderate disease and ICU has been recommended for patients with severe COVID-19, they added.